SOURCE: GeneThera, Inc.

June 07, 2007 13:48 ET

GeneThera's Update on Operations in Mexico

WHEAT RIDGE, CO--(Marketwire - June 7, 2007) - GeneThera, Inc. (OTCBB: GTHA) is pleased to announce an update to operations in Mexico. GeneThera and its subsidiary ApiGen have entered into an agreement to initiate a marketing trial for Johnne's Disease. GeneThera will deploy its Field Collection System (FCS) to ranchers throughout Mexico for GeneThera's diagnostic assay testing for Johnne's Disease.

The lab will open September 24, 2007. Phase One of the lab operation will be a marketing trial to be conducted over the course of 6 months. At the conclusion of the marketing trial, GeneThera will begin full operations for the testing of Johnne's Disease. The Mexican lab will begin processing 25 - 50 tests per day during the initial phase of the marketing trial. The lab will have a capacity of 2,000 tests per day once full operation is reached.

GeneThera expects to have 500 tests completed by December 3, 2007 with the lab at full capacity by February 29, 2008. GeneThera (through ApiGen) will collect $22 per test. The Mexican operations expected to generate $440,000 in revenue in its initial 12 months. The revenue over the initial 36 months is expected to exceed $9,500,000.

The costs for the Mexican operations for the next 12 months are $1,500,000. The costs include $250,000 for the equipment and $1,250,000 for the continued operations. The expected goals of GeneThera's Mexican Operations are: (1) to establish validation for the detection of Johnne's Disease and (2) to establish a vaccine and assay development for Johnne's Disease.


GeneThera, Inc. is a biotechnology company that develops molecular testing and DNA vaccines for animal diseases that may cause diseases in humans. The core of its operation is the ongoing development of molecular diagnostic assays using Real Time Fluorogenic Polymerase Chain Reaction (F-PCR) technologies to detect the presence of infectious disease from the blood of animals, particularly, live animals.

Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995:

This press release contains, and GeneThera may from time to time make, written or oral "forward-looking statements" within the meaning of the U.S. federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside GeneThera's control, that could cause actual results to differ materially from such statements. In particular, statements using words such as "may," "should," "estimate," "expect," "anticipate," "intend," "believe," "predict," "potential," or words of similar import generally involve forward-looking statements.

Contact Information